Development of weekly high-dose calcitriol based therapy for prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 21, Issue 5, 2003, Pages 399-405

  Beer, Tomasz M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; CALCITRIOL; CALCITRIOL DERIVATIVE; CYTOTOXIC AGENT; DEXAMETHASONE; DN 101; DOCETAXEL; LIGAND; MITOXANTRONE; PACLITAXEL; PLACEBO; PLATINUM DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR;

ALOPECIA; ANEMIA; ANGINA PECTORIS; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE PAIN; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE; CELL PROLIFERATION; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; CYTOTOXICITY; DEEP VEIN THROMBOSIS; DERMATITIS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DYSPNEA; EDEMA; FATIGUE; GASTRITIS; HERPES ZOSTER; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERGLYCEMIA; HYPOCALCEMIA; IN VITRO STUDY; IN VIVO CULTURE; INFECTION; LEUKOPENIA; NAUSEA; NEPHROLITHIASIS; NEUTROPENIA; NONHUMAN; ONYCHOLYSIS; PANCREATITIS; PEPTIC ULCER; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; TASTE DISORDER; TOXICITY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCITRIOL; CALCIUM; CELL DIVISION; CELL SURVIVAL; CLINICAL TRIALS; DISEASE PROGRESSION; HUMANS; LIGANDS; MALE; PLACEBOS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; TAXOIDS; TIME FACTORS;

EID: 2042424723     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(03)00170-4     Document Type: Conference Paper

References (61)

1. Mangelsdorf D.J., Thummel C., Beato M., et al. The nuclear receptor superfamily the second decade. Cell. 83:1995;835-839
2. Stumpf W.E., Sar M., Reid F.A. Target cells for 1, 25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, parathyroid. Science. 206:1979;1188-1190
3. Holick M.F. Noncalcemic actions of 1, 25-dihydroxyvitamin D3 and clinical applications. Bone. 17:1995;107S-111S
4. Abe E., Miyaura C., Sakagami H. Differentiation of rat myc leukemia cells induced by 1, 25-dihydroxyvitamin D3. Proceedings of the National Academy of Sciences USA. 78:1981;4990-4994
5. Colston K.W., Chander S.K., Mackay A.G., Coombes R.C. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol. 44:1992;693-702
6. Higashimoto Y., Ohata M., Nishio K., et al. 1 alpha, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. Anticancer Res. 16:1996;2653-2659
7. Konety B.R., Lavelle J.P., Pirtskalaishvili G., et al. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol. 165:2001;253-258
8. Cross H.S., Huber C., Peterlik M. Antiproliferative effect of 1, 25-dihydroxyvitamin D3 and its analogs on human colon adenocarcinoma cells (CaCo-2) influence of extracellular calcium. Biochem Biophys Res Commun. 179:1991;57-62
9. Zugmaier G., Jager R., Grage B., Gottardis M.M., Havemann K., Knabbe C. Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. Br J Cancer. 73:1996;1341-1346
10. Yabushita H., Hirata M., Noguchi M., Nakanishi M. Vitamin D receptor in endometrial carcinoma and the differentiation-inducing effect of 1, 25-dihydroxyvitamin D3 on endometrial carcinoma cell lines. J Obstet Gynaecol Res. 22:1996;529-539
11. Abe E., Miyaura C., Sakagami H., et al. Differentiation of mouse myeloid leukemia cells induced by 1 alpha, 25-dihydroxyvitamin D3. Proc Natl Acad Sci USA. 78:1981;4990-4994
12. Colston K., Colston M.J., Feldman D. 1, 25-dihydroxyvitamin D3 and malignant melanoma the presence of receptors and inhibition of cell growth in culture. Endocrinology. 108:1981;1083-1086
13. Shabahang M., Buffan A.E., Nolla J.M., et al. The effect of 1, 25-dihydroxyvitamin D3 on the growth of soft-tissue sarcoma cells as mediated by the vitamin D receptor. Ann Surg Oncol. 3:1996;144-149
14. Tokuumi Y. [Correlation between the concentration of 1, 25 alpha dihydroxyvitamin D3 receptors and growth inhibition, and differentiation of human osteosarcoma cells induced by vitamin D3]. Nippon Seikeigeka Gakkai Zasshi. 69:1995;181-190
15. Skowronski R.J., Peehl D.M., Feldman D. Vitamin D and prostate cancer 1, 25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology. 132:1993;1952-1960
16. Peehl D.M., Skowronski R.J., Leung G.K., Wong S.T., Stamey T.A., Feldman D. Antiproliferative effects of 1, 25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res. 54:1994;805-810
17. Schwartz G.G., Oeler T.A., Uskokovic M.R., Bahnson R.R. Human prostate cancer cells inhibition of proliferation by vitamin D analogs. Anticancer Res. 14:1994;1077-1081
18. Skowronski R.J., Peehl D.M., Feldman D. Actions of vitamin D3, analogs on human prostate cancer cell lines comparison with 1, 25-dihydroxyvitamin D3. Endocrinology. 136:1995;20-26
19. Hedlund T.E., Moffatt K.A., Miller G.J. Vitamin D receptor expression is required for growth modulation by 1 alpha, 25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol. 58:1996;277-288
20. Zhuang S.H., Schwartz G.G., Cameron D., Burnstein K.L. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol. 126:1997;83-90
21. Getzenberg R.H., Light B.W., Lapco P.E., et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology. 50:1997;999-1006
22. Campbell M.J., Koeffler H.P. Toward therapeutic intervention of cancer by vitamin D compounds. J Natl Cancer Inst. 89:1997;182-185
23. Liu M., Lee M.H., Cohen M., Bommakanti M., Freedman L.P. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 10:1996;142-153
24. Hengst L., Reed S.I. Translational control of p27Kip1 accumulation during the cell cycle. Science. 271:1996;1861-1864
25. Hershberger P.A., Yu W.D., Modzelewski R.A., Rueger R.M., Johnson C.S., Trump D.L. Calcitriol (1, 25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res. 7:2001;1043-1051
26. Kobayashi T., Hashimoto K., Yoshikawa K. Growth inhibition of human keratinocytes by 1, 25-dihydroxyvitamin D3 is linked to dephosphorylation of retinoblastoma gene product. Biochem Biophys Res Commun. 196:1993;487-493
27. James S.Y., Mackay A.G., Colston K.W. Effects of 1, 25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. Journal of Steroid Biochem Molec Biol. 58:1996;395-401
28. Guzey M., Kitada S., Reed J.C. Apoptosis induction by 1alpha, 25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther. 1:2002;667-677
29. Majewski S., Szmurlo A., Marczak M., Jablonska S., Bollag W. Inhibition of tumor cell-induced angiogenesis by retinoids, 1, 25-dihydroxyvitamin D3 and their combination. Cancer Lett. 75:1993;35-39
30. Mantell D.J., Owens P.E., Bundred N.J., Mawer E.B., Canfield A.E. 1 alpha, 25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res. 87:2000;214-220
31. Park W.H., Seol J.G., Kim E.S., et al. Induction of apoptosis by vitamin D3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase. Br J Haematol. 109:2000;576-583
32. Tang W., Ziboh V.A., Isseroff R.R., Martinez D. Novel regulatory actions of 1 alpha, 25-dihydroxyvitamin D3 on the metabolism of polyphosphoinositides in murine epidermal keratinocytes. J Cell Physiol. 132:1987;131-136
33. Haugen J.D., Pittelkow M.R., Zinsmeister A.R., Kumar R. 1 alpha, 25-dihydroxyvitamin D3 inhibits normal human keratinocyte growth by increasing transforming growth factor beta 2 release. Biochem Biophys Res Commun. 229:1996;618-623
34. Kim H.J., Abdelkader N., Katz M., McLane J.A. 1, 25-Dihydroxy-vitamin-D3 enhances antiproliferative effect and transcription of TGF-beta1 on human keratinocytes in culture. J Cell Physiol. 151:1992;579-587
35. Vink-van Wijngaarden T., Pols H.A., Buurman C.J., Birkenhager J.C., van Leeuwen J.P. Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1, 25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089. Eur J Cancer. 32A:1996;842-848
36. Drivdahl R.H., Loop S.M., Andress D.L., Ostenson R.C. IGF-binding proteins in human prostate tumor cells expression and regulation by 1, 25-dihydroxyvitamin D3. Prostate. 26:1995;72-79
37. Yu W.D., McElwain M.C., Modzelewski R.A., et al. Enhancement of 1, 25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. J Natl Cancer Inst. 90:1998;134-141
38. Bernardi R.J., Trump D.L., Yu W.D., McGuire T.F., Hershberger P.A., Johnson C.S. Combination of 1alpha, 25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis role of nuclear receptor cross-talk and Erk/Akt signaling. Clin Cancer Res. 7:2001;4164-4173
39. Hershberger P.A., Modzelewski R.A., Shurin Z.R., Rueger R.M., Trump D.L., Johnson C.S. 1, 25-Dihydroxycholecalciferol (1, 25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res. 59:1999;2644-2649
40. Bernardi R.J., Johnson C.S., Modzelewski R.A., Trump D.L. Antiproliferative effects of 1alpha, 25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology. 143:2002;2508-2514
41. Beer T.M., Hough K.M., Garzotto M., Lowe B.A., Henner W.D. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol. 28:2001;49-55
42. Moffatt K.A., Johannes W.U., Miller G.J. 1Alpha, 25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res. 5:1999;695-703
43. Ahmed S., Johnson C.S., Rueger R.M., Trump D.L. Calcitriol (1, 25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model. J Urol. 168:2002;756-761
44. Light B.W., Yu W.D., McElwain M.C., Russell D.M., Trump D.L., Johnson C.S. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res. 57:1997;3759-3764
45. Wieder R., Wang Q., Uytingco M., et al. 1, 25-dihydroxyvitamin D3 and all-trans retinoic acid promote apoptosis ans sensitize breast cancer cells to the effects of chemotherapeutic agents. Proceedings of ASCO. 17:1998;107a
46. Sundaram S., Chaudhry M., Reardon D., Gupta M., Gewirtz D.A. The vitamin D3 analog EB 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells. Breast Cancer Res Treat. 63:2000;1-10
47. Torres R., Calle C., Aller P., Mata F. Etoposide stimulates 1, 25-dihydroxyvitamin D3 differentiation activity, hormone binding and hormone receptor expression in HL-60 human promyelocytic cells. Mol Cell Biochem. 208:2000;157-162
48. Yu W.D., McGuire T.F., Hershberger P.A., Trump D.L., Johnson C.S. Paclitaxel enhances 1, 25-dihydroxyvitamin D3-induced apoptosis Inhibition of survival signals and up-regulation of MEKK-1 and p73. Proc Am Assoc Cancer Res. 43:2002;434
49. Osborn J.L., Schwartz G.G., Smith D.C., Bahnson R., Day R., Trump D.L. Phase II trial of oral 1, 25-dihydroxyvitamin D (Calcitriol) in hormone refractory prostate cancer. Urol Onc. 1:1995;195-198
50. Gross C., Stamey T., Hancock S., Feldman D. Treatment of early recurrent prostate cancer with 1, 25-dihydroxyvitamin D3 (calcitriol). J Urol. 159:1998;2035-2039. discussion 2039-2040
51. Papapoulos S.E., Clemens T.L., Sandler L.M., Fraher L.J., Winer J., O'Riordan J.L. The effect of renal function on changes in circulating concentrations of 1, 25-dihydroxycholecalciferol after an oral dose. Clin Sci. 62:1982;427-429
52. Smith D.C., Johnson C.S., Freeman C.C., Muindi J., Wilson J.W., Trump D.L. A Phase I trial of calcitriol (1, 25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res. 5:1999;1339-1345
53. Beer T.M., Munar M., Henner W.D. A Phase I trial of pulse calcitriol in patients with refractory malignancies pulse dosing permits substantial dose escalation. Cancer. 91:2001;2431-2439
54. Gordon N.H., Willson J.K. Using toxicity grades in the design and analysis of cancer phase I clinical trials. Stat Med. 11:1992;2063-2075
55. Storer B.E. Design and analysis of phase I clinical trials. Biometrics. 45:1989;925-937
56. Beer T.M., Lemmon D., Lowe B.A., Henner W.D. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer. 97:2003;1217-1224
57. Picus J., Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer preliminary results. Semin Oncol. 26:1999;14-18
58. Friedland D., Cohen J., Miller R. Jr, et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol. 26:1999;19-23
59. Beer T.M., Pierce W.C., Lowe B.A., Henner W.D. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol. 12:2001;1273-1279
60. Berry W., Dakhil S., Gregurich M.A., Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol. 28:2001;8-15
61. Beer T.M., Eilers K.M., Garzotto M., Egorin M.J., Lowe B.A., Henner W.D. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol. 21:2003;123-128